Dr. Jaroslaw Maciejewski, MD

• Hematology & Oncology

*Healthgrades does not verify qualifications for medical specialties. Please verify your provider's specialty and qualifications directly with your provider and applicable medical board.

• Humboldt University

  Medical School, 1988

• Somatic Mutations and Clonal Hematopoiesis in Aplastic Anemia, 2015-07-02

• Transcriptomic rationale for synthetic lethality-targetingERCC1andCDKN1Ain chronic myelomonocytic leukaemia, 2018-05-24

• Rare germline variant contributions to myeloid malignancy susceptibility, 2020-01-07

• From Bench to Bedside and Beyond: Therapeutic Scenario in Acute Myeloid Leukemia, 2020-02-04

• The functional mechanisms of mutations in myelodysplastic syndrome, 2019-10-31

• Runx1repression by histone deacetylation is critical forSetbp1-induced mouse myeloid leukemia development, 2015-07-24

• Molecular patterns identify distinct subclasses of myeloid neoplasia, 2023-05-30

• TP53Mutations in Myeloid Malignancies are either Homozygous or Hemizygous due to Copy Number-Neutral Loss of Heterozygosity or Deletion of 17p, 2009-09-17

• Distinctive and common features of moderate aplastic anaemia, 2020-01-31

• Relationship of paroxysmal nocturnal hemoglobinuria (PNH) granulocyte clone size to disease burden and risk of major vascular events in untreated patients: results from the International PNH Registry, 2023-05-18

• Implication ofPIGAgenotype on erythrocytes phenotype in Paroxysmal Nocturnal Hemoglobinuria, 2021-01-22

• Seroreactivity to LGL Leukemia-specific Epitopes in Aplastic Anemia, Myelodysplastic Syndrome and Paroxysmal Nocturnal Hemoglobinuria: Results of a Bone Marrow Failure Consortium Study, 2012-03-02

• Genomic Biomarkers to Predict Resistance to Hypomethylating Agents in Patients With Myelodysplastic Syndromes Using Artificial Intelligence, 2019-09-20

• Targeting of CD38 by the tumor suppressor miR-26a serves as a novel potential therapeutic agent in multiple myeloma, 2020-03-19

• IDH1/2mutations sensitize acute myeloid leukemia to PARP inhibition and this is reversed by IDH1/2-mutant inhibitors, 2018-01-16

• A Therapeutic Strategy for Preferential Targeting of TET2 Mutant and TET-dioxygenase Deficient Cells in Myeloid Neoplasms, 2020-12-07

• Distinct mutational pattern of myelodysplastic syndromes with and without 5q- treated with lenalidomide, 2020-03-09

• Spectrum of mutations in RARS-T patients includesTET2andASXL1mutations, 2010-03-23

• Novel Scheme for Defining the Clinical Implications ofTP53Mutations in Myeloid Neoplasia, 2023-03-09

• Somatic mutations in lymphocytes in patients with immune-mediated aplastic anemia, 2021-03-30

• Methylome profiling reveals distinct alterations in phenotypic and mutational subgroups of myeloproliferative neoplasms, 2012-10-11

• Impact of germlineCTC1alterations on telomere length in acquired bone marrow failure, 2019-03-19

• Pathogenesis and Consequences of Uniparental Disomy in Cancer, 2011-04-25

• CLINICAL AND BIOLOGICAL IMPLICATIONS OF ANCESTRAL AND NON-ANCESTRALIDH1ANDIDH2MUTATIONS IN MYELOID NEOPLASMS, 2015-04-03

• Inherited and somatic defects inDDX41in myeloid neoplasms, 2015-04-23

• The novel autophagy inhibitor ROC-325 augments the anti-leukemic activity of azacitidine, 2019-07-29

• Eltrombopag inhibits TET dioxygenase to contribute to hematopoietic stem cell expansion in aplastic anemia, 2022-02-15

• Ubiquitination of the spliceosome auxiliary factor hnRNPA1 by TRAF6 links chronic innate immune signaling with hematopoietic defects and myelodysplasia, 2016-12-26

• Casitas B-cell lymphoma mutation in childhood T-cell acute lymphoblastic leukemia, 2012-05-14

• SomaticSETBP1mutations in myeloid malignancies, 2013-07-07

• Outcomes of patients with myelodysplastic syndromes who achieve stable disease after treatment with hypomethylating agents, 2015-12-22

• FISH and SNP-A karyotyping in myelodysplastic syndromes: improving cytogenetic detection of del(5q), monosomy 7, del(7q), trisomy 8, and del(20q), 2009-09-15

• Baseline clinical characteristics and disease burden in patients with paroxysmal nocturnal hemoglobinuria (PNH): updated analysis from the International PNH Registry, 2020-05-10

• Analysis of distinctSF3B1hotspot mutations in relation to clinical phenotypes and response to therapy in myeloid neoplasia, 2020-11-03

• Multiple Myeloma Therapy: Emerging Trends and Challenges, 2022-08-23

• The NEDD8-activating enzyme inhibitor MLN4924 disrupts nucleotide metabolism and augments the efficacy of cytarabine, 2014-11-11

• Mybexpression is critical for myeloid leukemia development induced bySetbp1activation, 2016-11-16

• Clonal trajectories and cellular dynamics of myeloid neoplasms withSF3B1mutations, 2021-02-18

• DDX41-related myeloid neoplasia, 2017-04-21

• Large granular lymphocytic leukemia coexists with myeloid clones and myelodysplastic syndrome, 2019-10-17

• Functional analyses of human LUC7-like proteins involved in splicing regulation and myeloid neoplasms, 2021-04-13

• SAR Insights Into TET2 Catalytic Domain Inhibition: Synthesis of 2-Hydroxy-4-Methylene-pentanedicarboxylates, 2021-04-20

• Reduced red blood cell surface level of Factor H as a mechanism underlying paroxysmal nocturnal hemoglobinuria, 2020-08-19

• Deletion of Ptpn1 induces myeloproliferative neoplasm, 2017-01-23

• Tet2loss leads to hypermutagenicity in haematopoietic stem/progenitor cells, 2017-04-25

• Invariant patterns of clonal succession determine specific clinical features of myelodysplastic syndromes, 2019-11-26

• ClonalPIGAmosaicism and dynamics in paroxysmal nocturnal hemoglobinuria, 2018-04-25

• Dynamics of clonal evolution in myelodysplastic syndromes, 2016-12-19

• Long-term safety and efficacy of sustained eculizumab treatment in patients with paroxysmal nocturnal haemoglobinuria, 2013-04-25

• BCORandBCORL1mutations in myelodysplastic syndromes (MDS): clonal architecture and impact on outcomes, 2019-01-08

• Myeloid malignancies with chromosome 5q deletions acquire a dependency on an intrachromosomal NF-?B gene network, 2014-09-04

• Is nature truly healing itself? Spontaneous remissions in Paroxysmal Nocturnal Hemoglobinuria, 2021-11-27

• Impaired hydroxylation of 5-methylcytosine in myeloid cancers with mutantTET2, 2010-12-09

• Fanconi Anemia germline variants as susceptibility factors in aplastic anemia, MDS and AML, 2017-12-16

• Hepatitis C Infection Associated with Acquired Pure Red Cell Aplasia, 2022-12-22

• CMML AND aCML: NOVEL PATHOGENETIC LESIONS, 2012-11-15

• Somatic Mutations and Clonal Hematopoiesis in Aplastic Anemia, 2015-10-22

• Decitabine maintains hematopoietic precursor self-renewal by preventing repression of stem cell genes by a differentiation inducing stimulus, 2010-05-25

• Clonal Dynamics of Aplastic Anemia/Paroxysmal Nocturnal Hemoglobinuria, 2019-12-28

• Sulfur Amino Acid Supplementation Abrogates Protective Effects of Caloric Restriction for Enhancing Bone Marrow Regrowth Following Ionizing Radiation, 2022-04-06

• Targeting IRAK1 as a therapeutic approach for Myelodysplastic Syndrome, 2013-07-08

• Single-cell characterization of leukemic and non-leukemic immune repertoires in CD8+T-cell large granular lymphocytic leukemia, 2022-04-11

• Novel scheme for defining the clinical implications ofTP53mutations in myeloid neoplasia, 2023-08-03

• Optimization of Therapy for Severe Aplastic Anemia Based on Clinical, Biological and Treatment Response Parameters: Conclusions of an International Working Group on Severe Aplastic Anemia Convened by the Blood and Marrow Transplant Clinical Trials Network, March 2010, 2010-10-27

• Activating somatic mutations outside the SH2-domain ofSTAT3in LGL-Leukemia, 2015-09-30

• Complete mutational spectrum of the autophagy interactome: a novel class of tumor suppressor genes in myeloid neoplasms, 2016-10-24

• Myelodysplastic syndromes with del(5q): A real-life study of determinants of long-term outcomes and response to lenalidomide, 2022-09-07

• Clinical features and treatment outcomes in large granular lymphocytic leukemia (LGLL), 2017-06-20

• Mutational Analysis of RNA Splicing Machinery Components in 206 Children with Myeloid Malignancies, 2012-06-28

• Molecular predictors of response in patients with myeloid neoplasms treated with lenalidomide, 2016-08-18

• Molecular landscape of immune pressure and escape in aplastic anemia, 2022-10-17

• Leukemia evolving from paroxysmal nocturnal hemoglobinuria, 2019-08-20

• SNP Array Karyotyping Allows for the Detection of Uniparental Disomy and Cryptic Chromosomal Abnormalities in MDS/MPD-U and MPD, 2007-11-21

• Lenalidomide Promotes p53 Degradation by Inhibiting MDM2 Auto-ubiquitination in Myelodysplastic Syndrome with Chromosome 5q Deletion, 2012-04-23

• Comparing the prognostic value of risk stratifying models for patients with lower-risk myelodysplastic syndromes: Is one model better?, 2015-08-11

• Large granular lymphocytic laeukemia after solid organ and haematopoietic stem cell transplantation, 2020-01-20

• Germline DDX41 mutations cause ineffective hematopoiesis and myelodysplasia, 2021-09-01

• Single Nucleotide Polymorphism Array Lesions,TET2, DNMT3A,ASXL1andCBLMutations Are Present in Systemic Mastocytosis, 2012-08-15

• Leukemia relapse via genetic immune escape after allogeneic hematopoietic cell transplantation, 2023-04-05

• Mutations in G protein beta subunits promote transformation and kinase inhibitor resistance, 2014-12-08

• Aberrant DNA Methylation Is Associated with a Poor Outcome in Juvenile Myelomonocytic Leukemia, 2015-12-31

• Leukemia relapse via genetic immune escape after allogeneic hematopoietic cell transplantation, 2023-05-31

• Comprehensive Transcriptomic Analysis of VISTA in Acute Myeloid Leukemia: Insights into Its Prognostic Value, 2022-11-28

• TP53Mutation Status Divides Myelodysplastic Syndromes with Complex Karyotypes into Distinct Prognostic Subgroups, 2019-01-11

• Risk of Acute Myeloid Leukemia and Myelodysplastic Syndrome After Autotransplants for Lymphomas and Plasma Cell Myeloma, 2018-07-19

• Frequency and perturbations of various peripheral blood cell populations before and after eculizumab treatment in paroxysmal nocturnal hemoglobinuria, 2020-12-08

• Context dependent effects of ascorbic acid treatment in TET2 mutant myeloid neoplasia, 2020-09-07

• 250K SNP array karyotyping identifies acquired uniparental disomy and homozygous mutations, including novel missense substitutions ofc-Cbl, in myeloid malignancies, 2008-12-15

• Mutations inDNMT3A,U2AF1, andEZH2identify intermediate-risk acute myeloid leukemia patients with poor outcome after CR1, 2018-01-10

• Expansion of Effector Memory Regulatory T-cells Represents A Novel Prognostic Factor in Lower Risk Myelodysplastic Syndrome, 2012-08-08

• Clinical and basic implications of dynamic T cell receptor clonotyping in hematopoietic cell transplantation, 2021-07-08

• Molecular pathogenesis of disease progression inMLL-rearranged AML, 2018-09-12

• Comprehensive quantitative proteomic profiling of the pharmacodynamic changes induced by MLN4924 in acute myeloid leukemia cells establishes rationale for its combination with azacitidine, 2015-09-15

• Consequences of mutantTET2on clonality and subclonal hierarchy, 2018-05-24

• Progressive chromatin repression and promoter methylation ofCTNNA1associated with advanced myeloid malignancies, 2009-10-13

• Progress in the molecular diagnostics of hematologic neoplasia, 2020-08-07

• Recurrent genetic defects on chromosome 5q in myeloid neoplasms, 2016-12-23

• New drugs for pharmacological extension of replicative life span in normal and progeroid cells, 2019-01-16